Hansa Biopharma Bags EUR115 Million Idefirix Licensing Deal in Europe, MENA
Idag, 08:10
02:10 AM EDT, 05/19/2026 (MT Newswires) -- Hansa Biopharma (HNSA.ST) said Tuesday it secured a 115 million-euro licensing deal with Belgium's Serb Pharmaceuticals for Idefirix, or imlifidase.
Under the deal, Serb will commercialize and develop the transplant drug in the European Union, the UK, Switzerland, Norway, Liechtenstein, Iceland, and the Middle East and North Africa.
The Swedish biopharmaceutical company will receive 110 million euros upfront and another 5 million euros tied to a European Medicines Agency filing for full approval. The transaction is expected to close within 60 days, subject to regulatory approvals.
Idefirix is conditionally approved in Europe for desensitization treatment in highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
Ämnen i artikeln
Hansa Biopharma Bags EUR115 Million Idefirix Licensing Deal in Europe, MENA
Idag, 08:10
02:10 AM EDT, 05/19/2026 (MT Newswires) -- Hansa Biopharma (HNSA.ST) said Tuesday it secured a 115 million-euro licensing deal with Belgium's Serb Pharmaceuticals for Idefirix, or imlifidase.
Under the deal, Serb will commercialize and develop the transplant drug in the European Union, the UK, Switzerland, Norway, Liechtenstein, Iceland, and the Middle East and North Africa.
The Swedish biopharmaceutical company will receive 110 million euros upfront and another 5 million euros tied to a European Medicines Agency filing for full approval. The transaction is expected to close within 60 days, subject to regulatory approvals.
Idefirix is conditionally approved in Europe for desensitization treatment in highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
Ämnen i artikeln
Marknadsöversikt
1 DAG %
Senast
1 mån
